Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients

D. Rossille (1, 2) , I. Azzaoui (1, 2) , A. L. Feldman (3) , M. J. Maurer (3) , G. Labouré (4) , M. Parrens (4) , C. Pangault (1, 2) , T. M. Habermann (3) , S. M. Ansell (3) , B. K. Link (5) , K. Tarte (1, 2) , T. E. Witzig (3) , T. Lamy (2) , S. L. Slager (3) , Mikaël Roussel (1, 2) , N. Milpied (4) , J. R. Cerhan (3) , T. Fest (2, 1)

1 MICMAC - Microenvironment, Cell Differentiation, Immunology and Cancer
2 CHU Pontchaillou [Rennes]
3 Mayo Clinic [Rochester]
4 CHU Bordeaux [Bordeaux]
5 University of Iowa [Iowa City]

Domains: Life Sciences [q-bio]; Cancer; Life Sciences [q-bio]; Human health and pathology; Hematology

D. Rossille, I. Azzaoui, A. L. Feldman, M. J. Maurer, G. Labouré, et al.. Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. Leukemia, 2017, 31 (4), pp.988-991. ⟨10.1038/leu.2016.385⟩. ⟨hal-01517052⟩